S 48168 (ARM 210)

· RyCarma Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for S 48168 (ARM 210), covering 2024-04-19 to 2024-04-19. Get the full timeline:

Most recent: Clinical Trial Update: S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM) [Phase 1]